Approval · Notice of Compliance 26649 · 2021

LYUMJEV: Notice of Compliance 26649

Issued September 14, 2021

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 26649
Date: September 14, 2021
Company: Eli Lilly Canada IncToronto, Ontario, Canada
Product type: Biologic
Submission: New Drug Submission (NDS)
Submission class: Other

Products in this notice

Brand	DIN	Status today
LYUMJEV	02520184	Approved
LYUMJEV	02520230	Approved
LYUMJEV	02520192	Approved
LYUMJEV	02520214	Approved
LYUMJEV	02520206	Approved
LYUMJEV	02520222	Approved

Medicinal ingredients

INSULIN LISPRO 100 UNIT per ML
INSULIN LISPRO 200 UNIT per ML